Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1998-06-25
2001-04-10
Marschel, Ardin H. (Department: 1631)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S004000, C436S501000
Reexamination Certificate
active
06214550
ABSTRACT:
TECHNICAL FIELD
The present invention is generally directed toward tumor identification, including tumor detection and characterization. The invention is more particularly related to characterizing DNA based upon principal components analysis of spectral data yielded by Fourier transform-infrared spectroscopy of DNA samples, in order to screen for a tumor or progression of a tumor to the metastatic state.
BACKGROUND OF THE INVENTION
Despite enormous expenditures of both financial and human resources over the last twenty-five plus years, the detection of new tumors or the recurrence of tumors remains an unfulfilled goal of humankind. Particularly frustrating is the fact that a number of cancers are treatable if detected at an early stage, but go undetected in many patients for lack of a reliable screening procedure. In addition, the need is acute for reliable screening procedures that discriminate non-metastatic primary tumors (or non-cancerous disease states) from metastatic tumors, or are predictive of progression to the metastatic state. Metastasis of tumors is a major cause of treatment failure in cancer patients. It is a complex process involving the detachment of cells from the primary neoplasm, their entrance into the circulation, and the eventual colonization of local and distant tissue sites.
Frequently, physicians must err on the side of caution, and request that a patient undergo surgical or other procedures that dramatically affects the patient's quality of life, without identification of the disease state as a tumor with a propensity to progress to the metastatic state. For illustrative purposes, two particular cancers, prostate and breast cancers, are described in more detail and are representative of cancers in need of new approaches, which the invention disclosed herein provides.
Prostate cancer is a leading cause of death in men. Thus, there is a keen interest in the etiology of this disease, as well as in the development of techniques for predicting its occurrence at early stages of oncogenesis. Little is known about the etiology of prostate cancer, the most prevalent form being adenocarcinoma. However, several studies have focused on inactivation of the tumor suppressor gene TP53 and altered DNA methylation patterns as possible factors. In addition, free radicals, arising from redox cycling of hormones, have recently been implicated in prostate cancer. This is consistent with evidence showing that the hydroxyl radical (.OH) produces mutagenic alterations in DNA, such as 8-hydroxyguanine (8-OH-Gua) and 8-hydroxyadenine (8-OH-Ade), that have been linked to carcinogenesis in a variety of studies. Despite these findings, virtually no understanding exists of the possible relationship between the .OH-modification of DNA and prostate cancer.
Prostate tissue may contain areas of benign prostatic hyperplasia (BPH), which is not regarded as a pre-malignant lesion, although it often accompanies prostate cancer. The etiology of BPH is unknown, as is its relationship to prostate cancer. Due to the difficulties in the current approaches to the diagnosis of prostate cancer, there is a need in the art for improved methods. The present invention fulfills this need, and further provides other related advantages.
Breast cancer is a leading cause of death in women and is the most common malignancy in women. The incidence for developing breast cancer is on the rise. One in nine women will be diagnosed with the disease. Standard approaches to treat breast cancer have centered around a combination of surgery, radiation and chemotherapy. In certain malignancies, these approaches have been successful and have effected a cure. However, when diagnosis is beyond a certain stage, breast cancer is most often incurable. Invasive ductal carcinoma is a common form of breast cancer which can metastasize. Alternative approaches to early detection are needed. Due to the difficulties in the current approaches to the diagnosis of breast cancer, there is a need in the art for improved methods. The present invention fulfills this need, and further provides other related advantages.
DNA is continually being modified by microenvironmental factors, thus creating vast numbers of modified structures (ref. 1,2). For example, the progression of primary breast cancer to the metastatic state was estimated to involve as many as several billion new DNA forms, many of which likely result from hydroxyl radical (.OH)-induced structural alterations (ref. 2). Progress has been made in analyzing low mass oligonucleotides (<1>10
3
base pairs) (ref. 3). However, the complexity and high masses of the cellular DNAs (≈6×10
6
base pairs) have hindered their structural elucidation. Consequently, an understanding of these DNAs had to be obtained primarily by using destructive techniques (chemical or enzymatic) that provide little information on intact structures potentially having important biological properties.
The development of an infrared microscope spectrometer (FIG.
14
), coupled with advanced computer software, made it possible to obtain Fourier transform-infrared (FT-IR) spectra from micrograms of cellular DNA (e.g., from biopsy specimens).
SUMMARY OF THE INVENTION
Briefly stated, the present invention provides methods for defining the state of tissue, and assessing the genotoxicity of an environment. The inventive methods are particularly well suited for differentiating a T-1 (primary, non-metastatic) tumor from a metastatic tumor. The invention is applicable to a wide variety of DNA samples and cancers, and to a wide variety of genotoxic environments.
In one aspect, the present invention employs the so-called “centroid” model (which may also be called the “sigmoid curve model”) with which tissue samples are analyzed. According to the centroid model, there is provided a method of screening for a tumor or tumor progression to the metastatic state comprising the steps of: (a) subjecting a DNA sample to Fourier transform-infrared (FT-IR) spectroscopy to produce FT-IR spectral data; (b) analyzing the FT-IR spectral data of step (a) by principal components analysis (PCA); and (c) comparing the PCA of step (b) to the PCA of FT-IR spectra for DNA samples from non-cancerous, non-metastatic tumor or metastatic tumor samples.
In another aspect, the present invention provides a so-called “ellipsoid model” for characterizing the state of a tissue. In this aspect, the invention provides a mathematical description corresponding to various defined states of a tissue of interest, i.e., a model. Defined states of a tissue include, e.g., normal prostate tissue, benign prostatic hyperplasia and metastatic prostate cancer, where “normal”, “benign hyperplasia” and “metastatic” are three “defined states”, and prostate tissue is the “tissue of interest”.
In brief, according to the ellipsoid model, the invention provides a method for defining the state, e.g., the physiological state, of a tissue, comprising the steps of:
(a) subjecting DNA from a first plurality of tissue samples to Fourier transform-infrared (FT-IR) spectroscopy to produce FT-IR spectral data;
(b) analyzing the FT-IR spectral data of step (a) by principal components analysis (PCA) to provide a principal component (PC) scores;
(c) applying cluster analysis to the PC scores of step (b) to distinguish outlier and non-outlier tissue samples; and
(d) generating an equation, called a first equation, that defines a multivariate version of a normal bell-shaped curve which best fits the PC values from the non-outlier tissue samples, where the first equation defines the state of the first plurality of tissue samples.
In another embodiment, the method further includes repeating steps (a) through (d) above with a second plurality of tissue samples, to provide a second equation, where the second equation defines the state of the second plurality of tissue samples. In another embodiment, the method further includes the step of applying multivariate discrimination analysis to the first and second equations, to provide first and second probability equations, re
Marschel Ardin H.
Pacific Northwest Research Institute
Seed Intellectual Property Law Group PLLC
LandOfFree
Methods of differentiating metastatic and non-metastatic tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of differentiating metastatic and non-metastatic tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of differentiating metastatic and non-metastatic tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2434949